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Abstract 
Background: Despite the durable viral suppression afforded by antiretroviral therapy, HIV-1 eradication will require 
strategies to target latently infected cells that persist in infected individuals. Protein kinase C (PKC) activation is a 
promising strategy to reactivate latent proviruses and allow for subsequent recognition and clearance of infected cells 
by the immune system. Ingenol derivatives are PKC agonists that induce latency reversal but also lead to T cell activa-
tion and the release of pro-inflammatory cytokines, which would be undesirable in vivo. In this work, we sought to 
identify compounds that would suppress pro-inflammatory cytokine production in the context of PKC activation.
Design and methods: We performed an in vitro screen to identify compounds that could dampen pro-inflamma-
tory cytokine release associated with T cell activation, using IL-6 as a model cytokine. We then tested the ability of 
the most promising screening hit, the FDA-approved Janus Kinase (JAK) inhibitor ruxolitinib, to diminish release of 
multiple cytokines and its effect on latency reversal using cells from HIV-1-positive, aviremic participants.
Results: We demonstrate that co-administration of ruxolitinib with ingenol-3,20-dibenzoate significantly reduces 
pro-inflammatory cytokine release without impairing latency reversal ex vivo.
Conclusion: The combination of ingenol compounds and JAK inhibition represents a novel strategy for HIV-1 
eradication.
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Background
Antiretroviral therapy (ART) blocks HIV-1 replication 
and allows for restoration of the circulating CD4+ T cell 
population in infected patients. However the virus per-
sists in long-lived cellular reservoirs [1–3]. While ART 
can continuously suppress viral replication for years or 
even decades, patients who stop therapy soon develop 
viremia and progress to overt immunodeficiency if 
ART is not restarted [4]. Cells harboring this transcrip-
tionally silent but inducible viral reservoir lack specific 
markers that would allow direct targeting in  vivo. This 
has informed a pharmacologic eradication strategy mak-
ing use of compounds to reverse the latent viral state 
and ‘unmask’ this reservoir [5]. HIV-1 infected cells 
could then be recognized and cleared via viral cytopathic 
effects or immune-mediated mechanisms, resulting in 
prolonged ART-free virologic remission. Several classes 
of latency-reversing agents (LRAs) have reached pilot 
clinical trials [6–11]. While LRAs have generally been 
well tolerated by study participants, to date no significant 
change in latent reservoir size has been observed in these 
trials.
Protein kinase C (PKC) agonists are a promising LRA 
class [12]. Ingenol derivatives appear more efficacious 
and less toxic in vitro than more widely studied PKC ago-
nists such as prostratin or bryostatin-1 [13–15]. Ingenol 
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mebutate is FDA approved as a topical therapy for actinic 
keratosis [16], and other ingenol compounds have had a 
wide variety of applications in traditional medicine [17]. 
We recently described the efficacy of ingenol-3,20-diben-
zoate, a PKC agonist isolated from Euphorbia plant spe-
cies, to induce viral transcription ex vivo in resting CD4+ 
T cells from HIV-1 infected patients [18]. Recent stud-
ies have identified the efficacy of PKC agonists includ-
ing bryostatin-1 and ingenol derivatives in combination 
with LRAs from other mechanistic classes in  vitro [12, 
19–21] as well as in vivo in a non-human primate model 
[22]. Activation of NF-kB signaling is thought to be the 
mechanism by which PKC agonists reactivate latent 
HIV-1 provirus [23, 24]. Cellular PKC isoforms activate 
transcription factors including NF-kB, AP-1 and NF-AT 
leading to T cell activation [25–28]. Through these same 
pathways however, some PKC agonists can induce pro-
inflammatory cytokine secretion [29, 30]. This could 
cause significant morbidity in  vivo and has precluded 
PKC activation as a viable latency reversal strategy in 
clinical trials to date.
One strategy to address cytokine release associated 
with PKC activation would be the addition of a second 
pharmacologic agent to attenuate a pro-inflammatory 
response. In the present study we hypothesized that 
select kinase inhibitors could be identified which would 
dampen PKC-induced pro-inflammatory cytokine secre-
tion. Our ultimate goal was to identify means of decreas-
ing cytokine release while preserving the LRA properties 
of PKC agonists. Our unbiased in vitro screen identified 
ruxolitinib, an FDA-approved drug targeting the Janus 
kinase–signal transducer and activator of transcription 
(JAK–STAT) pathway. FDA-approved JAK inhibitors effi-
ciently block pro-inflammatory cytokine release from T 
cells in vivo in the context of myelofibrosis [31] and rheu-
matoid arthritis [32].
This strategy has not been previously explored in 
the context of HIV eradication and represents a novel 
approach to access the potential of PKC activation in the 
clinic. Here we demonstrate that JAK inhibition using 
the FDA-approved drug ruxolitinib is capable of decreas-
ing ingenol-induced pro-inflammatory cytokine release 
without significantly reducing latency reversal in resting 




Healthy donors and aviremic HIV-1 infected patients 
on ART were recruited for phlebotomy according to 
two approved Institutional Review Board (IRB) proto-
cols at the University of Utah as described previously 
[18]. Inclusion criteria for HIV-1 infected participants 
required viral suppression (less than 50 HIV-1 RNA 
copies/mL) for a minimum of 6 months, ART initiation 
during chronic HIV-1 infection (>6  months since sero-
conversion), and compliance with a stable ART regimen 
for a minimum of 12  months per participant and pro-
vider report. Informed consent and phlebotomy were 
performed in the Center for Clinical and Translational 
Science Clinical Services Core at the University of Utah 
Medical Center.
Reagents
Bryostatin-1, prostratin, ingenol-3,20-dibenzoate and 
ingenol-3-hexanoate, also known as ingenol B, were 
obtained from the Martin Delaney Collaboratory of 
AIDS Researchers for Eradication (CARE) Pharmacol-
ogy Core, University of North Carolina, Chapel Hill, NC. 
The kinase inhibitor library was obtained from the Uni-
versity of Utah Drug Discovery Core Facility. CD3/CD28 
antibody-coated magnetic beads (Dynabeads® Human 
T-Activator CD3/CD28) were purchased from Life Tech-
nologies (ThermoFisher Scientific). Ruxolitinib was pur-
chased from LC Laboratories, Woburn MA.
Cell culture and qPCR
The REVEAL assay was performed as described pre-
viously [18]. In brief, resting CD4+ T cells (rCD4s) 
were isolated from peripheral blood mononuclear cells 
(PBMCs) obtained from aviremic HIV+ donors. Ali-
quots of 5  ×  106 rCD4s were cultured under multi-
ple conditions: a negative control consisting of culture 
medium and dimethyl sulfoxide (DMSO; compound 
solvent), ingenol-3,20-dibenzoate (100  nM), ingenol 
B (100  nM), or CD3/CD28 antibody-coated magnetic 
beads (positive control). At 72  h, real time quantitative 
polymerase chain reaction (qPCR) was performed on 
culture supernatant to quantify viral release from rCD4 
cells. In order to evaluate cytokine release from PBMCs, 
five million PBMCs were cultured in 1 mL RPMI-based 
culture media supplemented with 10% fetal calf serum. 
At 72  h culture supernatant was harvested and spun 
down to remove cellular debris. 350  μL of cell-free 
supernatant was processed for cytokine quantification 
described below.
Cytokine measurement
Cytokines were measured in 350  μL aliquots of in  vitro 
culture supernatant by means of a commercially avail-
able quantitative multiplex bead assay performed by the 
clinical reference laboratory associated with the Univer-
sity of Utah Medical Center, ARUP Laboratories. ARUP 
Cytokine Panel 12 was developed and performance char-
acteristics determined by ARUP laboratories for evalua-
tion of immune, infectious or inflammatory disorders in 
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clinical or research settings, and measures the following 
cytokines: soluble interleukin 2 receptor (CD25), inter-
leukin 12 (IL-12), interferon gamma (IFNγ), interleukin 4 
(IL-4), interleukin 5 (IL-5), interleukin 10 (IL-10), inter-
leukin 13 (IL-13), interleukin 1 beta (IL-1β), interleukin 
6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor alpha 
(TNFα), and interleukin 2 (IL-2).
PKC agonist in vitro dose–response
A dose–response experiment was conducted in order 
to compare the pro-inflammatory cytokine induc-
tion profiles of PKC agonists that have been shown to 
reactivate latent HIV in  vitro (bryostatin-1, prostratin 
and ingenol-3,20-dibenzoate). PBMCs from aviremic 
HIV-1 positive donors were exposed to three concen-
trations of each of these PKC agonists and cytokine 
concentrations in culture supernatant were evalu-
ated at 72 h using the quantitative multiplex bead assay 
described above. LRAs were tested at concentrations 
shown to be active in reversing latency as well as one 
log higher and one log lower than this active concentra-
tion (ingenol-3,20-dibenzoate: 10 nM/100 nM/1000 nM; 
bryostatin-1: 1  nM/10  nM/100  nM; prostratin: 
30 nM/300 nM/3000 nM).
Individual cell cytokine production (In vitro)
Changes in intracellular TNFα and IFNγ levels in CD4, 
CD8, CD11b, and CD56 positive cells were examined to 
determine the effect of ingenol-3,20-dibenzoate and CD3/
CD28 antibody-coated magnetic beads on the induction 
of pro-inflammatory cytokines in individual cell types. 
PBMCs were isolated from the whole blood of two healthy 
donors using a Lymphoprep density gradient (Cat# 
07861, StemCell Technologies). 5  ×  106 total PBMCs 
were cultured for 72 h in the presence or absence of inge-
nol-3,20-dibenzoate (100  nM) or CD3/CD28 antibody-
coated magnetic beads. At 64 h post-stimulant exposure, 
0.067  μL/1  ×  105 BD GolgiStop™ Protein Transport 
Inhibitor (Cat# 554724) was added to each sample to pre-
vent cytokine release. Adherent cells were removed from 
the cell culture plate with StemPro® Accutase® cell disso-
ciation reagent (Cat# A1110501, Gibco™) prior to treat-
ment of total PBMCs with human FcR blocking reagent 
(Cat# 130-059-901, MACS Miltenyi Biotec). Cells were 
washed with 1× phosphate buffered saline (PBS) + 0.1% 
sodium azide prior to staining with 0.1  µL/1 ×  105 Fix-
able Viability Dye eFluor® 450 (Cat# 65-0863-14, Affym-
etrix eBioscience) for 30 min at 4°. Cells were then washed 
with 1× PBS + 0.1% sodium azide prior to staining cells 
in 100 µL 1× PBS + 0.1% sodium azide plus 0.5 µL CD4 
[CD4 antibody, PE (Cat# MHCD0404, Invitrogen)], 
0.5  µL CD8 [PE mouse anti-human CD8 (Cat# 557086, 
BD Pharmingen™)], 2 µL CD11b [PE mouse anti-human 
CD11b/Mac-1 (Cat# 561001, BD Pharmingen™)], or 3 µL 
CD56 [PE anti-human CD56 (NCAM) (Cat# 31805, Bio-
legend®)] for 30 min at 4 °C. Cells were then washed and 
fixed with 100  µL BD Cytofix/Cytoperm ™ Fixation and 
Permeabilization Solution  (Cat# 554722) for 30  min at 
4 °C. After fixation, cells were washed with a perm/wash 
solution (1× PBS, 3% FBS, 0.1% Saponin, 0.05% Sodium 
Azide) prior to staining cells in 100 µL perm/wash solu-
tion plus 2 µL TNFα [FITC anti-human TNF-α antibody 
(Cat# 502906, Biolegend®)] or 3  µL IFNγ [Alexa Fluor® 
488 mouse anti-human IFN-γ antibody (Cat# 557718, 
BD Pharmingen™)] overnight at 4  °C. Cells were washed 
and re-suspended in 1× PBS prior to conducting flow 
cytometry [BD FACSCanto flow cytometer with FACS-
Diva acquisition software (Becton–Dickinson, Mountain 
View, CA)] and analysis with FlowJo (TreeStar Inc, Ash-
land, OR). Changes in TNFα and IFNγ percent positive 
cells (fold change) were calculated for each cell type (CD4, 
CD8, CD11b, CD56) in ingenol-3,20-dibenzoate- and 
CD3/CD28 antibody-treated cells compared to media 
alone.
In vitro kinase inhibitor screening
Healthy donor PBMCs were isolated as described above. 
Isolated PBMCs were cultured overnight to allow mono-
cyte adherence. Non-adherent PBMCs were then cul-
tured in aliquots of 105 cells for 1.5  h at 37  °C in the 
presence of compounds identified as potential reducers 
of cytokine release from a literature search and from a 
kinase inhibitor library (EMD Millipore; obtained from 
University of Utah Drug Discovery Core Facility). 159 
compounds (Additional file 1: Table 1) were screened at 
a concentration of 10  µM. Aliquots were then exposed 
to various stimulant conditions: a negative control of 
culture medium and dimethyl sulfoxide (DMSO; com-
pound solvent), a positive control consisting of medium 
and CD3/CD28 antibody-coated magnetic beads, and 
medium containing 100 nM ingenol-3,20-dibenzoate. At 
40  h post-stimulant exposure, BD GolgiStop™ Protein 
Transport Inhibitor was added to each sample. At 48  h 
post-exposure cells were fixed and stained prior to flow 
cytometry analysis.
In vitro screening flow cytometry
At 48 h post-stimulant exposure cells were washed with 
1× PBS prior to staining with Fixable Viability Dye 
eFluor® 450. Cells were washed with 1× PBS prior to 
fixation and washing with perm/wash solution. Cells 
were stained in 100 µL perm/wash with 0.5 µL APC anti-
human IL-6 antibody (Cat# 501112, Biolegend®) over-
night at 4 °C. Cells were washed with perm/wash solution 
prior to re-suspension in 1× PBS. Flow cytometry was 
performed as described above.
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Selection of compounds
Cellular IL-sixfold change was determined by comparing 
the percentage of IL-6-positive cells in ingenol-3,20-diben-
zoate-treated cells (control) to kinase inhibitor + ingenol-
3,20-dibenzoate-treated cells. Compounds that reduced 
cytokine release (‘hits’) were selected for further study 
based on the following criteria: reduction of IL-6 by four-
fold and high cellular viability (>70%).
Apoptosis and activation flow cytometry
After 48 h in vitro under control and ingenol exposures, 
aliquots of 105 rCD4 cells were fixed using BD Cytofix™ 
Fixation Buffer (50% by volume; BD Biosciences) for 
10 min at 37  °C. After incubation, DMSO (Fisher Scien-
tific) was added to the sample to a final concentration of 
10% and frozen at −80  °C. At the time of analysis, sam-
ples were thawed on ice and re-suspended in 2 mL of PBS. 
500 μL aliquots were used for each staining and staining 
control. For acetyl-Histone H3 analysis, samples were 
pelleted and re-suspended in 100  μL of BD Phosflow™ 
Perm Buffer III (BD Biosciences, Cat# 558050) while vor-
texing, and incubated on ice for 30 min. Cells were then 
washed with PBS and incubated in 100 μL of PBS + 3% 
fetal bovine serum (FBS) containing 1  μL of acetyl-His-
tone H3-PE (Millipore, Cat# FCABS325PE) and 0.75  μL 
of cleaved caspase 3-AF488 (Cell Signaling Technology, 
Cat# 9669) for 1  h at room temperature protected from 
light. After incubation, cells were washed with PBS + 3% 
FBS and 100 μL of 2% paraformaldehyde (PFA) was added 
prior to flow cytometry acquisition. For CD69 analysis, 
samples were pelleted and re-suspended in 100  μL of 
BD Cytofix/Cytoperm™ (BD Biosciences, Cat# 554722) 
and incubated at 4 °C for 30 min. Cells were then washed 
with BD Perm/Wash™ (BD Biosciences, Cat# 554723) and 
incubated in 100 μL of Perm/Wash™ containing 1 μL of 
CD69-APC (Invitrogen, Cat# MHCD6905) and 0.75  μL 
of cleaved caspase 3-AF488 for 1 h at room temperature 
protected from light. After incubation, cells were washed 
with Perm/Wash buffer and 100 μL of 2% PFA was added 
prior to flow cytometry acquisition.
Statistical analysis
Pair-wise comparisons of cytokine concentrations 
(Figs.  1b, 4) and HIV-1 viral release (Figs.  1a, 3) under 
different experimental and control conditions were per-
formed using a non-parametric Wilcoxon matched-
pairs signed rank test. Flow cytometric measurements 
of CD69 expression and activated caspase 3 (Fig. 5) were 
evaluated using a paired t test. Individual measurements 
of cytokine concentrations, flow cytometry and qPCR 
values were tabulated and evaluated for statistical signifi-
cance using software from GraphPad Prism Version 5.0f 
(GraphPad Software, San Diego CA).
Results
Ingenol-3,20-dibenzoate and ingenol B have been shown 
to induce proviral transcription in resting CD4+ T cells 
from aviremic participants on ART [13–15, 18], how-
ever concomitant pro-inflammatory cytokine upregula-
tion characteristic of PKC agonists represent a significant 
barrier to their application as latency reversing agents 
in  vivo. We initially sought to characterize the degree 








































Fig. 1 Ingenol dibenzoate reverses latency ex vivo and induces pro-
inflammatory cytokine release. Ingenol-3,20-dibenzoate (ingenol DB) 
induced viral release from resting CD4+ T cells isolated from aviremic 
HIV-1 positive donors (n = 7; a) into culture supernatant to levels sim-
ilar to positive control (T cell receptor stimulation via CD3 and CD28 
antibodies, P value = 0.84) and significantly above the media alone 
condition (negative control; P value = 0.04). Ingenol B induced viral 
release in a minority of donor cultures and did not differ significantly 
from negative control (P value = 0.31). Despite differences in latency 
reversal, concentrations of pro-inflammatory cytokines TNFα, IFNγ, 
IL-1β and IL-6 were significantly elevated by both ingenol DB and 
ingenol B compared to negative control at 72 h in the supernatant 
of PBMCs from the same participants (b). Mean values and standard 
deviation are shown. Pro-inflammatory cytokine concentrations were 
significantly elevated in positive control cultures to levels similar to 
both ingenol conditions. *P value <0.05; **P value <0.01
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to which these compounds induce viral reactivation and 
pro-inflammatory cytokine release using cells obtained 
from aviremic participants on ART (Fig.  1). Using the 
REVEAL assay [18], we found that ingenol-3,20-diben-
zoate (100 nM) reproducibly led to latency reversal with 
levels of viral release significantly above background 
(P value  =  0.04) and similar to positive control (P 
value = 0.84; Fig. 1a), while ingenol B (100 nM) did not 
induce viral release to levels significantly above medium-
alone negative control cultures (P value = 0.31).
PBMCs from the same donors were cultured with 
ingenol-3,20-dibenzoate or ingenol B (100  nM for both 
drugs) for 72  h (Fig.  1b). Pro-inflammatory cytokine 
concentrations were measured from cell-free culture 
supernatant. Compared to medium-alone controls, both 
ingenol-3,20-dibenzoate and ingenol B significantly 
increased TNFα, IFNγ, IL-1β and IL-6 to concentrations 
similar to those observed after T cell receptor stimulation 
with CD3/CD28 antibodies (positive control) in PBMCs. 
Pro-inflammatory cytokine production in PBMC cul-
tures exposed to ingenol-3,20-dibenzoate was driven by 
CD8+ and CD56+ cells, while T cell receptor stimulation 
resulted in pro-inflammatory cytokine production from 
CD4+, CD8+, CD56+ and to a lesser extent CD11b+ cells 
(Additional file  2: Figure  1). In contrast, pro-inflamma-
tory cytokines were not induced when purified resting 
CD4+ T cells were incubated with either ingenol spe-
cies (Additional file 3: Figure 2). Ingenol-3,20-dibenzoate 
induced higher cytokine release than other PKC agonists 
tested, namely prostratin and bryostatin-1, at concentra-
tions known to reverse latency in vitro (Additional file 4: 
Figure 3).
We then conducted a small screen among known 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Kinase inhibitor screening identifies compounds that attenuate ingenol-induced cytokine release. Screening for changes in IL-6 production 
in healthy donor PBMCs exposed to ingenol-3,20-dibenzoate and 159 kinase inhibitors reveals twelve ‘hits’ that decrease intracellular IL-6 concen-
trations at least fourfold compared to ingenol-3,20-dibenzoate alone. Compounds are identified by Chemical Abstracts Service (CAS) number and 
color-coded by known function. Four of the twelve hits demonstrated high cellular viability (71–78%). Compound 941678-49-5, a Janus Kinase 
inhibitor, also known as ruxolitinib and FDA-approved for the treatment of myelofibrosis, was selected for additional experiments
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pro-inflammatory cytokine release in the presence of 
ingenol-3,20-dibenzoate (Fig.  2). Healthy donor PBMCs 
were cultured with ingenol-3,20-dibenzoate (100  nM) 
along with compounds from a library of known kinase 
inhibitors. IL-6 was chosen as a representative pro-
inflammatory cytokine for this screen. Intracellular IL-6 
expression was measured by flow cytometry at 48 h. 159 
compounds were screened in total. Twelve compounds 
(7.5%) reduced intracellular IL-6 expression by at least 
fourfold. Compound hits included three cyclin depend-
ent kinase (CDK) inhibitors (Chemical Abstracts Service 
(CAS)# 784211-09-2; 852529-97-0; 443797-96-4), five 
protein kinase inhibitors (CAS# 103745-39-7, 608512-
97-6; 127243-85-0; 136194-77-9, 257879-35-9), one 
inhibitor of phosphorylation of IκB (CAS# 19542-67-7), 
two glycogen synthase kinase 3 beta (GSK-3β) inhibitors 
(CAS# 237430-03-4; 327036-89-5), and a Janus kinase 
(JAK) inhibitor (CAS# 941678-49-5) (Fig. 2). Among the 
twelve compounds, eight compounds demonstrated low 
cellular viability (10-39% viability) and four demonstrated 
high cellular viability (71–78% viable; CAS# 136194-77-
9, 257879-35-9, 941678-49-5, 103745-39-7). Two of these 
were identified as PKC inhibitors and were therefore not 
pursued further (CAS# 136194-77-9; 257879-35-9). The 
two remaining compounds included CAS# 941678-49-5, 
a Janus kinase inhibitor also known as ruxolitinib, and 
103745-39-7, a Protein Kinase A (PKA)/Protein Kinase 
G (PKG) inhibitor. Ruxolitinib is FDA-approved for the 
treatment of myelofibrosis and was previously shown 
to efficiently block pro-inflammatory cytokine release 
from T cells in vivo in the context of myelofibrosis [31]. 
Ruxolitinib has favorable pharmacokinetics and a well-
characterized in  vivo safety profile [33], and therefore 
represented a promising candidate to attenuate ingenol-
induced pro-inflammatory cytokine induction.
Based on these results, we performed the REVEAL 
assay using resting CD4+ T cells from aviremic partici-
pants on ART (n  =  7) to evaluate whether ruxolitinib 
(100 nM) affected latency reversal by ingenol-3,20-diben-
zoate (100  nM). Ingenol-3,20-dibenzoate was selected 
based on its ability to induce viral release to a similar 
degree to T cell receptor stimulation (Fig.  1a). Cultures 
exposed to ingenol-3,20-dibenzoate plus ruxolitinib 
demonstrated no significant change with respect to viral 
release compared to culture conditions not containing 
ingenol-3,20-dibenzoate alone (Fig. 3).
We then sought to test whether the ability of ruxoli-
tinib to suppress IL-6 secretion in the context of ingenol-
3,20-dibenzoate would apply to other pro-inflammatory 
cytokines. To that end, we tested TNFα, IFNγ, IL-1β and 
IL-6 secretion in cells from HIV-1-infected aviremic 
patients. We observed that the secretion of these pro-
inflammatory cytokines (all upregulated by ingenol 
derivatives, Fig.  1b) decreased significantly in the pres-
ence of ruxolitinib (Fig.  4). Ruxolitinib also suppressed 































Ing DB    Ing DB + Rx αCD3/28 αCD3/28 + Rx
Fig. 3 Ruxolitinib does not affect viral release from resting CD4+ 
T cells. No significant change in HIV-1 viral release was observed in 
resting CD4+ T cell cultures exposed to ingenol-3,20-dibenzoate (Ing 
DB) or antibodies against CD3 and CD28 (αCD3/28, positive control) 
in the presence of ruxolitinib (Rx) compared to Ing DB or αCD3/28 
alone. Horizontal bars represent geometric mean values within each 
culture condition. Resting CD4+ T cells were obtained from aviremic 
ART-treated individuals cultured ex vivo (n = 7)
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Fig. 4 Ruxolitinib significantly decreases ingenol-induced cytokine 
release. Bars represent the median change in pro-inflammatory 
cytokine concentrations in PBMC cultures exposed to ruxoli-
tinib + ingenol-3,20-dibenzoate (ingenol DB) compared to ingenol 
DB alone. PBMCs from aviremic ART-treated individuals (n = 7) were 
cultured for 72 h. One standard deviation shown by error bars. *P 
value <0.05; **P value <0.01
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levels of IL-2, IL-4, IL-8, IL-10, or IL-12 in the setting of 
ingenol exposure (Additional file  5: Figure  4a). Ruxoli-
tinib demonstrated less efficacy at reducing T cell recep-
tor stimulation-induced pro-inflammatory cytokine 
release (Additional file  5: Figure  4b). For example, IL-6 
and IL-1β concentrations were not significantly altered 
by the addition of ruxolitinib to αCD3/CD28-exposed 
cultures (in contrast to significant reductions observed in 
ingenol-exposed cultures shown in Fig.  4). This may be 
due to the pleiotropic effects of T cell receptor stimula-
tion on cellular activation pathways and is the subject of 
ongoing study.
We have previously observed that CD69, a cell surface 
protein upregulated early in T cell activation, serves as 
a biomarker of PKC activation with ingenol compounds 
[18]. Furthermore, these compounds do not induce 
apoptosis in resting CD4+ T cells above baseline (meas-
ured by activated caspase 3) or loss of viability in general 
[18]. We sought to determine whether exposure to rux-
olitinib would affect caspase activation or CD69 expres-
sion (Fig.  5). Addition of 100  nM ruxolitinib to resting 
CD4+ T cell cultures from aviremic participants on ART 
(n = 4) exposed to 100 nM ingenol-3,20-dibenzoate dem-
onstrated no significant changes with respect to the per-
centage of cells expressing activated caspase 3 (Fig.  5a), 
CD69, or the mean florescence intensity of CD69 expres-
sion (Fig.  5b). Viability measured by forward- and side-
scatter gating via flow cytometry ranged between 89 and 
93% across conditions and was not statistically different 
between them (data not shown). We conclude that rux-
olitinib does not alter the apoptosis threshold or influ-
ence CD69 expression in CD4+ T cells in the context of 
ingenol 3,20 dibenzoate exposure.
Discussion
The earliest clinical trials attempting to perturb the 
HIV-1 latent reservoir in vivo made use of a strategy of 
global T cell activation and resulted in significant toxicity, 
due in part to induction of pro-inflammatory cytokines 
[34, 35]. Subsequent clinical trials have tested LRAs that 
induce minimal T cell activation including histone dea-
cetylase inhibitors and disulfiram, however these trials 
did not demonstrate perturbation of the latent reservoir 
in vivo [11]. The modest results of these trials support the 
need for a different approach to latency reversal involv-
ing strong activators. In a comparative analysis across 
multiple in vitro latency model systems and in cells from 
aviremic patients ex  vivo, PKC agonists were the only 
LRA class to consistently demonstrate latency reversal, 
aside from T cell receptor engagement [36].
PKC agonists, and ingenol compounds in particu-
lar, are promising candidate latency reversal agents for 
HIV-1 eradication [23]. However, their in  vivo utility as 
LRAs could be compromised by induction of pro-inflam-
matory cytokine release common to many protein kinase 
C agonists. We propose a novel approach to address this 
potentially toxic adverse effect of an otherwise promis-



















Media Ingenol DB αCD3/28
24.1 23.0 98.8 98.5 98.7 98.5
Fig. 5 Ruxolitinib does not alter apoptosis threshold or CD69 expression in the presence of ingenol-3,20-dibenzoate. Ruxolitinib (100 nM) did 
not significantly alter the percentage of resting CD4+ T cells expressing activated caspase 3 (a) or expression of CD69 (represented as the mean 
florescence intensity or MFI with the total percentage of cells in each culture condition expressing CD69 within each bar; b) in the presence of 
ingenol-3,20-dibenzoate (ingenol DB). Mean values and standard deviation are shown for four independent experiments using resting CD4+ T cells 
from aviremic ART-treated participants (n = 4)
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drug ruxolitinib does not significantly affect the latency 
reversing potential of ingenol-3,20-dibenzoate ex  vivo 
using resting CD4+ T cells from aviremic HIV-1 posi-
tive individuals on ART. Previously published work dem-
onstrated that ruxolitinib inhibited latency reversal in a 
primary cell latency model when used at high concen-
trations (1 μM and greater) [37]. At 100 nM, Gavegnano 
et al. [37] reported only 20% inhibition of viral reactiva-
tion, whereas we observed no significant inhibition of 
latency reversal at that same concentration. Ruxolitinib 
does however effectively decrease ingenol-induced pro-
inflammatory cytokine release.
In vitro cell culture assays manipulating cytokine 
release are imperfect models of cytokine storm in  vivo. 
Future studies evaluating the potential role of Janus 
kinase inhibition in attenuating PKC-induced cytokine 
release in non-human in vivo HIV-1 latency models are 
an important next step toward furthering this potential 
clinical strategy. Further studies will also be required to 
determine the dose–response relationship between rux-
olitinib and cytokine suppression in PBMCs. This in turn 
will inform whether ruxolitinib, at concentrations achiev-
able in vivo, can decrease PKC-induced cytokine stimu-
lation to levels that would allow these latency reversing 
agents to be tolerated in pilot clinical trials.
Conclusion
JAK inhibition decreases ingenol-induced pro-inflam-
matory cytokine release without significantly reducing 
latency reversal in resting CD4+ T cells from aviremic 
HIV-1 positive patients on ART ex  vivo. Co-adminis-
tration of the FDA-approved Janus kinase inhibitor 
ruxolitinib may help to overcome a major barrier to the 
use of ingenol compounds (or other PKC agonists) as 
latency reversal agents for pilot HIV-1 eradication clin-
ical trials.
Authors’ contributions
AMS, ETL, AB and VP designed this research study. AMS, ETL, MLC, ABM and 
LJM conducted experiments, acquired and analyzed data. AMS, ETL and VP 
wrote and revised the manuscript and accompanying figures. All authors read 
and approved the final manuscript.
Author details
1 Department of Medicine, University of Utah School of Medicine, Salt Lake 
City, UT, USA. 2 Department of Pathology, University of Utah School of Medi-
cine, Emma Eccles Jones Medical Research Building Room 2520, 15 North 
Medical Drive East, Salt Lake City, UT 84112, USA. 
Acknowledgements
The authors are grateful to our study participants for their willingness to take 
part in ongoing translational research including the experiments described 
in this manuscript. We greatly appreciate all of the help we received from our 
research coordinator Hina Yazdani, colleagues in University of Utah Clinic 1A 
and the University of Utah Center for Clinical and Translational Science (CCTS) 
Clinical Services Core. Angela Presson from the University of Utah Study 
Design and Biostatistics Center (SDBC) offered valuable input regarding statis-
tical considerations. We are grateful to Jerry L. Spivak, M.D. of Johns Hopkins 
University School of Medicine for providing insight into novel applications of 
Janus kinase inhibition.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article and supplementary figures.
Ethics approval and consent to participate
Healthy donors and aviremic HIV-1 infected patients on ART were recruited 
for phlebotomy according to two approved Institutional Review Board (IRB) 
protocols at the University of Utah as described previously [18].
Additional files
Additional file 1: Table 1. Compounds screened in the kinase inhibi-
tor library. Compounds are listed by Chemical Abstracts Service (CAS) 
number in the order shown in Fig. 2 along with the compound’s common 
names, known functions, and if they were observed to reduce IC IL-6 
levels by ≥fourfold.
Additional file 2: Figure 1. Ingenol-3,20-dibenzoate (Ingenol DB) and 
CD3/CD28 antibody-induced fold changes in TNFα and IFNγ among 
peripheral blood cell subsets. Ingenol DB and CD3/28 antibodies 
increased the number of TNFα and IFNγ positive CD8+ and CD56+ cells 
compared to media alone at 72 h post-stimulation in two donors. CD3/
CD28 antibody treatment increased the number of TNFα and IFNγ posi-
tive CD4+ cells, whereas ingenol DB treatment decreased the number 
of cytokine positive cells in both donors, likely due to a down-regulation 
of CD4 upon ingenol DB treatment [30]. TNFα and IFNγ positive CD11b+ 
cells varied between donors.
Additional file 3: Figure 2. Ingenols do not induce pro-inflammatory 
cytokine release in purified resting CD4+ T cell cultures. Concentra-
tions of pro-inflammatory cytokines TNFα, IFNγ, IL-1β and IL-6 were not 
significantly elevated in the presence of ingenol-3,20-dibenzoate (ingenol 
DB) or ingenol B compared to media alone control at 72 h in purified 
resting CD4+ T cell cultures. Mean values and standard deviation of seven 
independent experiments using resting CD4+ T cells from aviremic ART-
treated HIV positive participants are shown. Pro-inflammatory cytokine 
concentrations were significantly elevated in positive control cultures (T 
cell receptor stimulation via CD3 and CD28 antibodies). ** P value <0.01; 
*** P value <0.001.
Additional file 4: Figure 3. PKC agonists induce pro-inflammatory 
cytokines in a dose-dependent manner. PBMCs from aviremic, HIV-
1-infected participants (n = 4) were exposed to PKC agonists ingenol-
3,20-dibenzoate, prostratin and bryostatin-1 at concentrations shown 
to reverse latency as well as tenfold higher and lower concentrations. 
Pro-inflammatory cytokine concentrations were measured in culture 
supernatant after 72 h in culture. Bars represent mean fold-change above 
cytokine concentrations from media-alone PBMC cultures (negative 
control) with one standard deviation shown. When comparing concentra-
tions of these PKC agonists previously shown to reverse viral latency, 
ingenol-3,20-dibenzoate demonstrated the highest pro-inflammatory 
cytokine induction.
Additional file 5: Figure 4. Ruxolitinib-induced cytokine changes in 
PBMCs from aviremic HIV-1 infected donors. CD25 (IL2r), IL-5, and IL-13 
concentrations were significantly decreased in PBMC cultures exposed to 
ruxolitinib + ingenol-3,20-dibenzoate compared to ingenol-3,20-dibenzo-
ate alone. Ruxolitinib significantly reduced these cytokine concentrations 
in CD3/28 antibody-treated PBMC cultures as well, along with reduction in 
IL-10. Ruxolitinib did not decrease pro-inflammatory cytokines induced by 
CD3/28 antibody stimulation to the same degree as ingenol-stimulated 
cells (shown in Fig. 4).
Page 9 of 9Spivak et al. Retrovirology  (2016) 13:88 
Funding
This work was supported in part by the National Institutes of Health (NIH) 
National Institute of Allergy and Infectious Diseases R21/R33 AI122377-01 (VP), 
NIH National Heart, Lung and Blood Institute Grant R01 HL126547 (VP, AMS), 
NIH National Center for Advancing Translational Sciences Grant 1KL2TR001065 
(AMS) and the Doris Duke Charitable Foundation Clinical Scientist Devel-
opment Award CSDA201612 (AMS). ETL is supported by the NIH National Insti-
tute of Allergy and Infectious Diseases Ruth L. Kirschstein National Research 
Service Award 2T32AI055434-11. These funding organizations played no role 
in the design of the study, collection, analysis or interpretation of data or 
the writing of this manuscript. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the NIH.
Received: 12 July 2016   Accepted: 25 November 2016
References
 1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establish-
ment of a pool of latently infected, resting CD4(+) T cells during primary 
HIV-1 infection. Proc Natl Acad Sci USA. 1998;95(15):8869–73.
 2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. 
Identification of a reservoir for HIV-1 in patients on highly active antiretro-
viral therapy. Science. 1997;278(5341):1295–300.
 3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. 
Recovery of replication-competent HIV despite prolonged suppression of 
plasma viremia. Science. 1997;278(5341):1291–5.
 4. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, 
et al. Rebound of plasma viremia following cessation of antiretroviral 
therapy despite profoundly low levels of HIV reservoir: implications for 
eradication. AIDS. 2010;24(18):2803–8.
 5. Deeks SG. HIV: shock and kill. Nature. 2012;487(7408):439–40.
 6. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. 
HIV-1 expression within resting CD4+ T cells after multiple doses of 
vorinostat. J Infect Dis. 2014;210(5):728–35.
 7. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valp-
roic acid in association with highly active antiretroviral therapy for reduc-
ing systemic HIV-1 reservoirs: results from a multicentre randomized 
clinical study. HIV Med. 2012;13(5):291–6.
 8. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, 
et al. Administration of vorinostat disrupts HIV-1 latency in patients on 
antiretroviral therapy. Nature. 2012;487(7408):482–5.
 9. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon 
A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus 
reactivation in HIV-infected patients on suppressive antiretroviral therapy: 
a phase 1/2, single group, clinical trial. Lancet HIV. 2014;1(1):e13–21.
 10. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot 
study assessing the safety and latency-reversing activity of disulfiram in HIV-
1-infected adults on antiretroviral therapy. Clin Infect Dis. 2014;58(6):883–90.
 11. Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations). 
Trends Mol Med. 2016;22(1):10–27.
 12. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. 
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combina-
tions. J Clin Investig. 2015;125(5):1901–12.
 13. Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, et al. 
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV rep-
lication: inhibition of de novo infection and activation of viral LTR. PLoS 
ONE. 2014;9(5):e97257.
 14. Jiang G, Mendes EA, Kaiser P, Sankaran-Walters S, Tang Y, Weber MG, et al. 
Reactivation of HIV latency by a newly modified Ingenol derivative via 
protein kinase Cδ–NF–κB signaling. AIDS. 2014;28(11):1555–66.
 15. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da 
Costa TB, et al. Reactivation of latent HIV-1 by new semi-synthetic ingenol 
esters. Virology. 2014;462–463:328–39.
 16. Alchin DR. Ingenol mebutate: a succinct review of a succinct therapy. 
Dermatol Ther. 2014;4(2):157–64.
 17. Ernst M, Grace OM, Saslis-Lagoudakis CH, Nilsson N, Simonsen HT, 
Ronsted N. Global medicinal uses of Euphorbia L. (Euphorbiaceae). J 
Ethnopharmacol. 2015;176:90–101.
 18. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo 
Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and 
Panobinostat in Resting CD4+ T Cells from Aviremic Patients. Antimicrob 
Agents Chemother. 2015;59(10):5984–91.
 19. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An 
In-depth comparison of latency-reversing agent combinations in various 
in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 
and ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS 
Pathog. 2015;11(7):e1005063.
 20. Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I, et al. Synergistic reac-
tivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted 
NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS 
Pathog. 2015;11(7):e1005066.
 21. Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido 
ML, Munoz-Fernandez MA, et al. Bryostatin-1 synergizes with histone 
deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res. 
2010;8(6):418–29.
 22. Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgrefe 
SW, O’Connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements 
JE, LRA-SIV Study Group. Reactivation of simian immunodeficiency virus 
reservoirs in the brain of virally suppressed macaques. AIDS. 2017;31(1):5-
14. doi:10.1097/QAD.0000000000001267
 23. Jiang G, Dandekar S. Targeting NF-κB signaling with protein kinase C 
agonists as an emerging strategy for combating HIV latency. AIDS Res 
Hum Retroviruses. 2015;31(1):4–12.
 24. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, et al. 
Prostratin antagonizes HIV latency by activating NF-κB. J Biol Chem. 
2004;279(40):42008–17.
 25. Genot EM, Parker PJ, Cantrell DA. Analysis of the role of protein 
kinase C-alpha, -epsilon, and -zeta in T cell activation. J Biol Chem. 
1995;270(17):9833–9.
 26. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA. Effects of prostratin 
on T-cell activation and human immunodeficiency virus latency. J Virol. 
2002;76(16):8118–23.
 27. Monks CR, Kupfer H, Tamir I, Barlow A, Kupfer A. Selective modula-
tion of protein kinase C-theta during T-cell activation. Nature. 
1997;385(6611):83–6.
 28. Sun Z, Arendt CW, Ellmeier W, Schaeffer EM, Sunshine MJ, Gandhi L, et al. 
PKC-theta is required for TCR-induced NF-κB activation in mature but not 
immature T lymphocytes. Nature. 2000;404(6776):402–7.
 29. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo 
approaches distinguish effective and ineffective single agents for revers-
ing HIV-1 latency in vivo. Nat Med. 2014;20(4):425–9.
 30. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, et al. 
Prostratin: activation of latent HIV-1 expression suggests a potential 
inductive adjuvant therapy for HAART. Blood. 2001;98(10):3006–15.
 31. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, 
Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 
inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–27.
 32. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. 
Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 
2014;370(25):2377–86.
 33. Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofi-
brosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother 
Pharmacol. 2016;77(6):1125–42.
 34. Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, et al. 
Intensification and stimulation therapy for human immunodeficiency 
virus type 1 reservoirs in infected persons receiving virally suppressive 
highly active antiretroviral therapy. J Infect Dis. 2002;186(10):1403–11.
 35. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, 
et al. Immuno-activation with anti-CD3 and recombinant human 
IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 
1999;13(17):2405–10.
 36. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. 
An in-depth comparison of latent HIV-1 reactivation in multiple cell 
model systems and resting CD4+ T cells from aviremic patients. PLoS 
Pathog. 2013;9(12):e1003834.
 37. Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. 
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 
replication and virus reactivation in vitro. Antimicrob Agents Chemother. 
2014;58(4):1977–86.
